December 13, 2024
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
GAITHERSBURG, Md., Dec. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced…
December 12, 2024
Washington’s 60 Degrees Pharmaceuticals Adds Brigham and Women’s Hospital to Tafenoquine Babesiosis Trial
WASHINGTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (60 Degrees Pharmaceuticals or the “Company”), a pharmaceutical…
December 11, 2024
Governor Moore Announces Maryland Soft Landing Exchange Business Incubator and Accelerator Program Now Open
ANNAPOLIS, MD – Governor Wes Moore today announced that applications are being accepted for the Maryland Soft Landing Exchange Program, which allows Maryland…
December 10, 2024
Emmes adds Bryan Patterson to lead as Senior Vice President of Government Business Development & Capture
Emmes®, part of Emmes Group®, a leading specialty tech and AI-enabled global contract research organization (CRO), today announced the appointment of…
December 10, 2024
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced…
December 10, 2024
Theradaptive Obtains FDA IDE Approval to Study OsteoAdapt™ SP in Additional Spinal Fusion Indications
FREDERICK, Md., Dec. 10, 2024 /PRNewswire/ -- Theradaptive, a privately held, clinical stage biologics company developing protein therapeutics for spine, orthopedics, soft…
December 10, 2024
BHI at TEDCO’s 10th Entrepreneur Expo: A Celebration of Maryland’s Innovation Ecosystem
On December 4th, TEDCO hosted its 10th Entrepreneur Expo in Baltimore, bringing together over 1,000 entrepreneurs, investors, and industry leaders…
December 10, 2024
NextCure Secures FDA IND Approval to Launch Phase 1 Trial of LNCB74 Antibody-Drug Conjugate for Cancer
BELTSVILLE, Md., Dec. 10, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel,…
December 10, 2024
Annapolis’ Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis
ANNAPOLIS, Md., Dec. 10, 2024 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and…